Britain and America have hammered out a important trade agreement that will maintain no tariffs on UK drug exports being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these key goods will stay at zero for a timeframe of 36 months.
This agreement follows previous warnings to significantly raise tariffs on patented drug products, with figures floated reaching one hundred percent.
"This agreement between the UK strengthens the worldwide climate for new treatments and brings long-overdue balance to U.S.–U.K. drug exports," a statement declared.
Economic Impact
Drugs represent one of the the United Kingdom's largest exports to the America, which is by far the primary market for major UK drugmakers.
Export figures indicate that in the year leading up to September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that period.
"This guarantee safeguards jobs, stimulates investment and paves the way for the UK to emerge as a global hub for medical research," a minister remarked.
Key UK Commitments
The pact involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments were more than twenty percent.
Industry Background
The pact follows a protracted row between the sector and the British authorities over medicine costs and approval rates.
This friction were exacerbated by arguments that US customers were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward US facilities.
A senior figure stated that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.
